Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: A tissue microarray study

American Journal of Clinical Pathology

Volumn 132, Issue 3, 2009, Pages 378-390

  Conesa Zamora, Pablo ^a   Doménech Peris, Asunción ^a   Orantes Casado, Francisco J ^a   Ortiz Reina, Sebastián ^a   Sahuquillo Frías, Laura ^a   Acosta Ortega, Jesús ^a   García Solano, José ^a   Pérez Guillermo, Miguel ^a  

^a Hospital Universitario Santa Maria del Rosell   (Spain)

Author keywords

Atypical immature metaplasia; Cell cycle; Cervical cancer; HPV genotype; Immunohistochemistry; ProEx C; Squamous intraepithelial lesion; Tissue microarray

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; KI 67 ANTIGEN; PROEX C PROTEIN; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; MCM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; P16 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE MICROARRAY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS IDENTIFICATION; VIRUS STRAIN; WART VIRUS; BIOSYNTHESIS; CELL CYCLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRECANCER; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ANTIGENS, NEOPLASM; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 69849109598     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPO0WY1VIFCYDC     Document Type: Article

References (37)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
2. Zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131-156. (Pubitemid 24099089)
3. Nam EJ, Kim JW, Kim SW, et al. The expressions of the Rb pathway in cervical intraepithelial neoplasia: predictive and prognostic significance. Gynecol Oncol. 2007;104:207-211. (Pubitemid 46054131)
4. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284. (Pubitemid 32225381)
5. Bae DS, Cho SB, Kim YJ, et al. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol. 2001;81:341-347.
6. Silva-Filho AL, Traiman P, Triginelli SA, et al. Expression of p53, Ki-67, and CD31 in the vaginal margins of radical hysterectomy in patients with stage IB carcinoma of the cervix. Gynecol Oncol. 2004;95:646-654. (Pubitemid 39592534)
7. Sarian LO, Derchain SF, Yoshida A, et al. Expression of cyclooxygenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix. Gynecol Oncol. 2006;102:537-541. (Pubitemid 44353650)
8. Vijayalakshmi N, Selvaluxmi G, Majhi U, et al. Alterations found in pl6/Rb/cyclin D1 pathway in the dysplastic and malignant cervical epithelium. Oncol Res. 2007;16:527-533. (Pubitemid 351211325)
9. Wells M, Östor AG, Crum CP, et al. Tumors of the uterine cervix: epithelial tumors. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:262-279. World Health Organization Classification of Tumours.
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
11. 1 cell cycle regulators in cervical neoplasm. Gynecol Oncol. 2003;91:476-485.
12. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 2003;63:1927-1935. (Pubitemid 36460860)
13. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291. (Pubitemid 40075455)
14. Romanowski P, Madine MA. Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6p and ORC. Trends Cell Biol. 1997;7:9-10. (Pubitemid 27056377)
15. Shi J, Liu H, Wilkerson M, et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol. 2007;38:1335-1344. (Pubitemid 47247476)
16. Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008;32:899-906.
17. Pinto AP, Schlecht NF, Woo TY, et al. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol. 2008;21:1067-1074.
18. Duggan MA, Akbari M, Magliocco AM. Atypical immature cervical metaplasia: immunoprofiling and longitudinal outcome. Hum Pathol. 2006;37:1473-1481. (Pubitemid 44584328)
19. Iaconis L, Hyjek E, Ellenson LH, et al. p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix: correlation with human papillomavirus detection. Arch Pathol Lab Med. 2007;131:1343-1349. (Pubitemid 47427587)
20. Geng L, Connolly DC, Isacson C, et al. Atypical immature metaplasia (AIM) of the cervix: is it related to high-grade squamous intraepithelial lesion (HSIL)? Hum Pathol. 1999;30:345-351. (Pubitemid 29125156)
21. Schneider V. Tissue microarrays for testing molecular biomarkers of cervical intraepithelial neoplasia: feasibility study. Acta Cytol. 2006;50:123-128.
22. Kim JY, Lim SJ, Park K, et al. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol. 2005;97:337-341. (Pubitemid 40614873)
23. Qiao X, Bhuiya TA, Spitzer M. Differentiating highgrade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis. J Low Genit Tract Dis. 2005;9:100-107. (Pubitemid 40464079)
24. Feng W, Xiao J, Zhang Z, et al. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Mod Pathol. 2007;20:961-966. (Pubitemid 47267824)
25. Zhao P, Mao X, Talbot IC. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol. 2006;12:6391-6396. (Pubitemid 44712426)
26. Emig R, Magener A, Ehemann V, et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer. 1998;78:1661-1668. (Pubitemid 28550055)
27. Bahnassy AA, Zekri AR, Saleh M, et al. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol. 2007;7:4. doi:10.1186/1472-6890-7-4. (Pubitemid 46972613)
28. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol. 1996;9:418-425. (Pubitemid 26153384)
29. Cheung TH, Yu MM, Lo KW, et al. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett. 2001;166:199-206.
30. Carreras R, Alameda F, Mancebo G, et al. A study of Ki-67, c-erbB2 and cyclin D-1 expression in CIN-I, CIN-III and squamous cell carcinoma of the cervix. Histol Histopathol. 2007;22:587-592. (Pubitemid 46647271)
31. Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812-821. (Pubitemid 23163585)
32. Hiller T, Poppelreuther S, Stubenrauch F, et al. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev. 2006;15:1262-1267. (Pubitemid 44125279)
33. Giarnieri E, Mancini R, Pisani T, et al. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res. 2000;6:3600-3606. (Pubitemid 30694943)
34. Conesa-Zamora P, Doménech-Peris A, Ortiz-Reina S, et al. Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol. 2009;62:159-162.
35. Ortiz M, Torres M, Muñoz L, et al. Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. Clin Microbiol. 2006;44:1428-1434.
36. Muñoz N, Bosch FX, de Sanjosé S, et al; for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
37. Miyatake T, Ueda Y, Yoshino K, et al. Clonality analysis and human papillomavirus infection in squamous metaplasia and atypical immature metaplasia of uterine cervix: is atypical immature metaplasia a precursor to cervical intraepithelial neoplasia 3? Int J Gynecol Pathol. 2007;26:180-187. (Pubitemid 46573216)